Go Deep
Bioventus Inc.
Bioventus Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,203 | 17.4 | 4.06 | 0.95 | 1,291.37 |
| Oct 2026 | 19,231 | 17.3 | 4.04 | 0.95 | 1,281.79 |
| Oct 2026 | 19,087 | 17.7 | 4.13 | 0.95 | 1,311.41 |
| Oct 2026 | 19,324 | 17.1 | 3.98 | 0.95 | 1,259.71 |
| Oct 2026 | 19,236 | 17.3 | 4.04 | 0.95 | 1,279.07 |
| Oct 2026 | 19,022 | 17.9 | 4.17 | 0.95 | 1,322.69 |
| Oct 2026 | 18,887 | 18.3 | 4.26 | 0.95 | 1,346.85 |
| Oct 2026 | 18,515 | 19.3 | 4.50 | 0.95 | 1,419.64 |
| Oct 2026 | 18,552 | 19.2 | 4.48 | 0.95 | 1,417.94 |
Bioventus Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 153,208,000.0 | 132,089,000.0 | 157,900,000.0 | 138,651,000.0 |
| Net Profit | 33,441,000.0 | 3,113,000.0 | 14,755,000.0 | 3,155,000.0 |
| EPS | 0.5 | 0.1 | 0.2 | 0.1 |
Bioventus Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 568,087,000.0 | 573,280,000.0 | 512,345,000.0 | 512,117,000.0 | — |
| Net Profit | 22,732,000.0 | -36,125,000.0 | -156,230,000.0 | -158,704,000.0 | — |
| EPS | 0.3 | -0.6 | -2.5 | -2.6 | — |
Bioventus Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 683,559,000.0 | 727,956,000.0 | 810,910,000.0 | 1,372,649,000.0 | — |
| Total Liabilities | 455,112,000.0 | 542,352,000.0 | 589,792,000.0 | 960,427,000.0 | — |
| Total Equity | 184,105,000.0 | 147,940,000.0 | 173,591,000.0 | 325,238,000.0 | — |
Owes vs Owns
Bioventus Inc. owed $0.59 for every $1 it owned in Jun 2026, down from $0.70 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.59× | 0.67× | 0.75× | 0.73× | 0.70× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Bioventus Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 7.5%Receivables 18.8%Inventory 12.0%Fixed assets (tangible) 4.0%Intangible assets 55.0%Other assets 2.8%
How it's funded — Dec 2025
Short-term debt 2.2%Long-term debt 40.8%Payables 1.6%Other liabilities 22.0%Shareholders' equity 33.4%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 51.2 | 41.6 | 37.0 | 30.2 |
| Receivables | 128.3 | 127.4 | 122.8 | 136.3 |
| Inventory | 82.2 | 92.5 | 91.3 | 84.8 |
| Fixed assets (tangible) | 27.0 | 33.5 | 50.0 | 44.1 |
| Intangible assets | 375.9 | 412.2 | 489.8 | 647.3 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 2.6 |
| Other assets | 18.9 | 20.8 | 20.1 | 427.3 |
| Liabilities & equity | ||||
| Short-term debt | 15.0 | 27.3 | 27.8 | 33.1 |
| Long-term debt | 279.0 | 308.3 | 367.0 | 385.0 |
| Payables | 10.9 | 23.7 | 23.0 | 36.7 |
| Other liabilities | 150.2 | 183.0 | 171.9 | 505.7 |
| Shareholders' equity | 228.4 | 185.6 | 221.1 | 412.2 |
| Net tangible assets | -191.8 | -264.3 | -316.2 | -322.1 |
Bioventus Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | 74,673,000.0 | 38,795,000.0 | 15,344,000.0 | -13,537,000.0 | — |
| Investing Activities | -3,248,000.0 | 22,963,000.0 | 15,807,000.0 | -116,436,000.0 | — |
| Financing Activities | -62,140,000.0 | -54,580,000.0 | -26,653,000.0 | 62,076,000.0 | — |